CLU and hepatocellular carcinoma: Clusterin, one of the CRPs, has been shown to promote the CSC properties of HCC, including chemoresistance, metastasis and tumourigenesis, by activating the AKT/GSK-3β/β-catenin axis, as demonstrated by in vitro and in vivo assays (55).